# NCT05194982 (NCT05194982)

> A Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Solid Tumor

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05194982
- Phase: PHASE1
- Status: RECRUITING
- Sponsor: Sichuan Baili Pharmaceutical Co., Ltd.
- Conditions: Locally Advanced or Metastatic Solid Tumor
- Interventions: BL-B01D1
- Enrollment: 570
- Primary outcome: Phase Ia: Dose limiting toxicity (DLT)
- Primary outcome: Phase Ia: Maximum tolerated dose (MTD)
- Primary outcome: Phase Ib: Recommended Phase II Dose (RP2D)

## Indexed commentary on NCT05194982 so far

Podcasts, YouTube videos and posts on X and Bluesky we have indexed that name the trial. LinkedIn posts are read for reports and the Enterprise MCP, not yet for this index. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 2 posts on Bluesky
- 1 post on X

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=nct05194982
